MARKET

CRDF

CRDF

Cardiff Oncology Inc
NASDAQ
1.050
-0.050
-4.55%
Closed 19:30 09/09 EDT
OPEN
1.080
PREV CLOSE
1.100
HIGH
1.080
LOW
1.020
VOLUME
715.99K
TURNOVER
0
52 WEEK HIGH
3.310
52 WEEK LOW
0.7566
MARKET CAP
81.69M
P/E (TTM)
-1.7757
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CRDF last week (0831-0904)?
Weekly Report · 2d ago
Weekly Report: what happened at CRDF last week (0824-0828)?
Weekly Report · 08/31 10:21
Weekly Report: what happened at CRDF last week (0817-0821)?
Weekly Report · 08/24 10:21
Cardiff Oncology downgraded to Market Perform from Outperform at William Blair
TipRanks · 08/17 11:06
Weekly Report: what happened at CRDF last week (0810-0814)?
Weekly Report · 08/17 10:22
Take-Two, Quantum, On, Cardiff, Autodesk Trending With Analysts
TipRanks · 08/15 09:01
Cardiff Oncology Cut to Market Perform From Outperform by William Blair
Dow Jones · 08/12 19:13
William Blair Downgrades Cardiff Oncology to Market Perform
Benzinga · 08/12 19:03
More
About CRDF
Cardiff Oncology, Inc. is a clinical-stage biotechnology company advancing cancer treatments focused on Polo-like Kinase 1 (PLK1) inhibition, a validated oncology target with practice-changing potential. The Company's lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor being evaluated in a Phase II trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also being evaluated in multiple other cancers through investigator-initiated studies, including metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), and chronic myelomonocytic leukemia (CMML). The Company's clinical development programs incorporate tumor genomics and biomarker assays to refine patient selection and assessment of patient response to treatment.

Webull offers Cardiff Oncology Inc stock information, including NASDAQ: CRDF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRDF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRDF stock methods without spending real money on the virtual paper trading platform.